- Few recurrences are local [renal bed]. Most are pulomary, hepatic, or bone.
- Disease specific cancer survival is stage dependent at 5 and 10 years
Stage 5 yrs 10 yrs I 90 80 II 80 70 III 50 35 IV 10 3 - Partial nephrectomy in <4 cm lesions has a disease free survival approaching 100% at 5 years
- Incidentally found, unilateral and small lesions perform best
Memorial Sloan-Kettering Nomogram
Researchers at Memorial Sloan-Kettering have developed a nomogram that combines prognostic factors to predict the likelihood of recurrence after surgery for renal cell carcinoma. This nomogram can be used to predict the five-year probability of treatment failure among patients with newly-diagnosed renal cell carcinoma.
http://www.mskcc.org/mskcc/html/6156.cfm
References
- Bostwick DG, Eble JN: Diagnosis and classification of renal cell carcinoma. Urol Clin N Am 26:627-635, 1999.
- Caddeddu JA, Ono Y, Clayman RV, et al: Laparoscopic nephrectomy for renal cell cancer: Evaluation of efficacy and safety: A multicenter experience. Urology 52:773-777, 1998.
- Levy DA, Slaton JW, Swanson DA, Dinney CP: Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 15:1163-1167, 1998.
- Montie JM: Lymphadenectomy for renal cell carcinoma. Semin Urol 7:181-185, 1989.
- Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med 335:865-875, 1996.
- Novick AC: Renal-sparing surgery for renal cell carcinoma. Urol Clin North Am 20:277-282, 1993.
- Sagalowsky AI, Kadesky KT, Ewalt DM, Kennedy TJ: Factors influencing adrenal metastasis in renal cell carcinoma. J Urol 151:1181-1184, 1994.
- Skinner DG, Pritchett RT, Lieskovsky G, Boyd SD, Stiles QR: Vena caval involvement by renal cell carcinoma. Surgical resection provides meaningful long-term survival. Ann Surg 210:387-394, 1989.
- Sufrin G, Cashon S, Golio A, Murphy GP: Paraneoplastic and serologic syndromes of renal adenocarcinoma. Semin Urol 7:158-171, 1989.
- Yang JC, Topalian SL, Parkinson D, et al: Randomized comparison of high-dose and low-dose intravenous interleukin 2 for the therapy of metastatic renal cell carcinoma: An interim report. J Clin Oncol 12:1572-1576, 1994.